Pressure
BioSciences Inc. Places Order for 40 NEP2320 Barocycler Units from Source
Scientific, LLC
WEST
BRIDGEWATER, Mass, June 28 /PRNewswire-FirstCall/ -- Pressure BioSciences,
Inc.
(Nasdaq: PBIO
-
News;
"PBI")
today announced that it has placed an order for 40 Barocycler NEP2320 units
with
Source Scientific, LLC, the manufacturer of the Company's PCT equipment and
disposables product line. The NEP2320 is the new, patent-pending, lightweight,
compressed air-driven pressure cycling instrument that the Company unveiled
last
month at the BIO2007 International Convention in Boston, MA.
The
Barocycler NEP2320 is a smaller, more compact version of the Company's existing
Barocycler instrument, the NEP3229. It has a similar "look and feel" to the
NEP3229, but offers a system weight of approximately 75 verses 350 pounds,
and
processes one sample at a time verses three for the NEP3229. Originally designed
to be a demonstration unit for the larger and higher throughput NEP3229, the
Company announced the decision to release the NEP2320 as a new product offering
after market research suggested that there may be a niche in genomics and
proteomics research laboratories for a Barocycler instrument with a lower sample
throughput and a lower price, but with many of the technical capabilities of
the
higher throughput Barocycler NEP3229.
Dr.
Nate
Lawrence, Vice President of Marketing and Sales for PBI, said: "The past six
weeks have helped confirm our market research that there may be a demand for
the
smaller, lighter, more compact NEP2320. We have seen interest from a number
of
places, including laboratories with multiple sites, laboratories with limited
space, laboratories with low sample throughput volumes that don't require the
larger NEP3229, and laboratories with budgetary constraints. These market data
have us more convinced than ever that there is a true and growing need for
the
NEP2320 in a variety of life sciences laboratories."
Richard
T. Schumacher, Founder, President, and CEO of PBI said: "We expect the first
of
the 40 instruments under this new purchase order to be delivered near the end
of
September or early October, 2007. Approximately 20 units are expected to be
delivered prior to December 31, 2007, with the remaining units being delivered
during the first quarter of 2008. A minimum of 10 of the units will be
configured for European electrical requirements, as we continue to prepare
for
the 2008 European launch of our PCT product line, as previously announced."
Schumacher
continued: "This new purchase order is in addition to our initial and previously
announced purchase order for nine NEP2320 demonstration instruments. The
delivery of the first two of these initial nine NEP2320 instruments has recently
allowed our sales staff to demonstrate the NEP2320 at potential customer sites,
a significant milestone. We continue to actively build a solid, well-seasoned,
well-trained sales force. We believe that the 40 NEP3229 instruments ordered
in
March, plus the nine initially ordered NEP2320 demonstration instruments and
the
40 additional NEP2320 instruments under this new purchase order will give us
the
inventory we need to follow-up aggressively during 2007 and into 2008 on the
large number of leads that have been generated over the past half year."
About
Pressure BioSciences, Inc.
Pressure
BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on
the
development of a novel, enabling technology called Pressure Cycling Technology
(PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high
levels (up to 35,000 psi and greater) to control bio-molecular interactions.
PBI
currently holds 13 US and 5 foreign patents covering multiple applications
of
PCT in the life sciences field, including such areas as genomic and proteomic
sample preparation, pathogen inactivation, the control of chemical reactions,
immunodiagnostics, and protein purification.
Forward
Looking Statements
Statements
contained in this press release regarding the Company's intentions, hopes,
beliefs, expectations, or predictions of the future are "forward-looking''
statements within the meaning of the Private Securities Litigation Reform Act
of
1995, including statements relating to the perceived demand for the smaller
and
lower cost NEP2320 instrument, the laboratories that may be interested in
purchasing the NEP2320 instrument, the expected delivery dates for the
instruments on order from Source Scientific LLC, any implication regarding
potential sales of the NEP2320 instrument or the NEP3229 instrument that are
under purchase order with Source Scientific LLC, and the Company's expectations
about the market interest generally in the PCT SPS. These statements are based
upon the Company's current expectations, forecasts, and assumptions that are
subject to risks, uncertainties, and other factors that could cause actual
outcomes and results to differ materially from those indicated by these
forward-looking statements. These risks, uncertainties, and other factors
include, but are not limited to: unforeseen technological difficulties that
the
Company may encounter in the development of the PCT technology and the NEP2320,
including cost overruns, technical risks, and manufacturing and other delays;
due to unforeseen technical, marketing, sales, and distribution difficulties,
PBI may not have sufficient financial resources to finance the commercialization
of PCT as currently planned; due to such unforeseen technical, marketing, sales,
and distribution difficulties, the recently announced PCT-dependent,
detergent-free method of protein extraction may not offer any advantages over
current methods of protein extraction; that the PCT-dependent, detergent-free
method of protein extraction may not be adopted by the scientific community
as
an accepted method of protein extraction; that the PCT-dependent, detergent-free
method of protein extraction may not help advance diabetes and other scientific
research; that the Company may not be successful in expanding its sales team
and
other sales capabilities as planned; and the other risks and uncertainties
discussed under the heading "Risk Factors" in the Company's Annual Report on
Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report
on Form 10- QSB for the quarter ended March 31, 2007, and other reports filed
by
the Company from time to time with the SEC. The Company undertakes no obligation
to update any of the information included in this release, except as otherwise
required by law.
Visit
us
at our website http://www.pressurebiosciences.com
Investor
Contacts:
Richard
T.
Schumacher, President & CEO
Pressure
BioSciences, Inc.
Edward
H.
Myles, Senior VP of Finance and CFO
(508)
580-1818 (T)